428 related articles for article (PubMed ID: 30974033)
61. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
Tonneijck L; Muskiet MHA; Smits MM; Bjornstad P; Kramer MHH; Diamant M; Hoorn EJ; Joles JA; van Raalte DH
Diabetes Obes Metab; 2018 May; 20(5):1235-1245. PubMed ID: 29341461
[TBL] [Abstract][Full Text] [Related]
62. Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review.
Guo X; Yang Q; Dong J; Liao L; Zhang W; Liu F
Clin Drug Investig; 2016 Jun; 36(6):433-41. PubMed ID: 26979594
[TBL] [Abstract][Full Text] [Related]
63. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.
Edelman SV
J Fam Pract; 2017 Oct; 66(10 Suppl):S12-S16. PubMed ID: 28991932
[TBL] [Abstract][Full Text] [Related]
64. GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials.
Tsapas A; Karagiannis T; Avgerinos I; Liakos A; Bekiari E
Diabetes Res Clin Pract; 2021 Jul; 177():108921. PubMed ID: 34144086
[TBL] [Abstract][Full Text] [Related]
65. Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes.
Storgaard H; Cold F; Gluud LL; Vilsbøll T; Knop FK
Diabetes Obes Metab; 2017 Jun; 19(6):906-908. PubMed ID: 28105738
[TBL] [Abstract][Full Text] [Related]
66. [Effects of GLP-1 receptor agonists on carbohydrate metabolism control].
Fernández-García JC; Colomo N; Tinahones FJ
Med Clin (Barc); 2014; 143 Suppl 2():18-22. PubMed ID: 25326839
[TBL] [Abstract][Full Text] [Related]
67. The cardiovascular effects of glucagon-like peptide-1 receptor agonists: a trial sequential analysis of randomized controlled trials.
Wu S; Sun F; Zhang Y; Yang Z; Hong T; Chen Y; Zhan S
J Clin Pharm Ther; 2014 Feb; 39(1):7-13. PubMed ID: 24127768
[TBL] [Abstract][Full Text] [Related]
68. The effect of glucagon-like peptide-1 receptor agonists on serum uric acid concentration: A systematic review and meta-analysis.
Najafi S; Bahrami M; Butler AE; Sahebkar A
Br J Clin Pharmacol; 2022 Aug; 88(8):3627-3637. PubMed ID: 35384008
[TBL] [Abstract][Full Text] [Related]
69. Glucagon-like peptide-1 receptor agonists and atrial fibrillation: a systematic review and meta-analysis of randomised controlled trials.
Monami M; Nreu B; Scatena A; Giannini S; Andreozzi F; Sesti G; Mannucci E
J Endocrinol Invest; 2017 Nov; 40(11):1251-1258. PubMed ID: 28569363
[TBL] [Abstract][Full Text] [Related]
70. Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials.
Hu W; Song R; Cheng R; Liu C; Guo R; Tang W; Zhang J; Zhao Q; Li X; Liu J
Front Endocrinol (Lausanne); 2022; 13():927859. PubMed ID: 35898463
[TBL] [Abstract][Full Text] [Related]
71. Effect of glucagon-like peptide 1 receptor agonists on albuminuria in adult patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Yuan D; Sharma H; Krishnan A; Vangaveti VN; Malabu UH
Diabetes Obes Metab; 2022 Sep; 24(9):1869-1881. PubMed ID: 35589615
[TBL] [Abstract][Full Text] [Related]
72. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
[TBL] [Abstract][Full Text] [Related]
73. Use of Glucagon-Like-Peptide 1 Receptor Agonists and Risk of Fracture as Compared to Use of Other Anti-hyperglycemic Drugs.
Driessen JH; van Onzenoort HA; Starup-Linde J; Henry R; Burden AM; Neef C; van den Bergh JP; Vestergaard P; de Vries F
Calcif Tissue Int; 2015 Nov; 97(5):506-15. PubMed ID: 26184119
[TBL] [Abstract][Full Text] [Related]
74. Cardiovascular safety and benefits of GLP-1 receptor agonists.
Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
[TBL] [Abstract][Full Text] [Related]
75. Effect of glucagon-like peptide-1 receptor agonists on fat distribution in patients with type 2 diabetes: A systematic review and meta-analysis.
Duan K; Yan X; Gao Z; Hou Y; Lv X; Song G
J Diabetes Investig; 2022 Jul; 13(7):1149-1160. PubMed ID: 35191185
[TBL] [Abstract][Full Text] [Related]
76. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
Tzefos M; Harris K; Brackett A
Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
[TBL] [Abstract][Full Text] [Related]
77. Glucagon-like Peptide-1 Receptor Agonists Cardio-protective Effects: An Umbrella Review.
Elnour AA; Al Hajri N; El Khidir IY; AlAmoodi A; Ahmed SA; Sadeq A
Curr Diabetes Rev; 2020; 16(8):820-832. PubMed ID: 32442089
[TBL] [Abstract][Full Text] [Related]
78. Network meta-analysis of the risk of dyspepsia and anorexia in patients with type 2 diabetes mellitus induced by glucagon-like peptide 1 receptor agonist hypoglycemic drugs.
Jiao BL; Zhao J; Wang B; Liu BY; Wu T
Eur Rev Med Pharmacol Sci; 2024 Apr; 28(8):3073-3084. PubMed ID: 38708466
[TBL] [Abstract][Full Text] [Related]
79. Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy.
Douros A; Filion KB; Yin H; Yu OH; Etminan M; Udell JA; Azoulay L
Diabetes Care; 2018 Nov; 41(11):2330-2338. PubMed ID: 30150234
[TBL] [Abstract][Full Text] [Related]
80. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis.
Ansari HUH; Qazi SU; Sajid F; Altaf Z; Ghazanfar S; Naveed N; Ashfaq AS; Siddiqui AH; Iqbal H; Qazi S
Endocr Pract; 2024 Feb; 30(2):160-171. PubMed ID: 38029929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]